Literature DB >> 16257150

Combination of anabolic and antiresorptive agents for the treatment of osteoporosis.

Carmen Garcés1, Luis-Emilio García.   

Abstract

Combination therapy strategies for osteoporosis are reviewed in this article. Regimens including two antiresorptives agents increase BMD more than single therapy alone, but they have not proved to reduce fracture risk. The alternative of combining antiresorptives together with anabolics has gained more interest. There are, however, many questions still pending, as which antiresorptive should be used, and the appropriate sequence of the treatments. It seems that bisphosphonates can blunt the anabolic effect of parathyroid hormone (PTH) when given simultaneously. Instead, when PTH follows the antiresorptive treatment the anabolic effect seems not to be blunted. Finally, other possible approach would be to initiate therapy with an anabolic agent and maintain the effect with any antiresorptive if necessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257150     DOI: 10.1016/j.maturitas.2005.08.011

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  2 in total

1.  Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  S Lou; H Lv; P Yin; Z Li; P Tang; Y Wang
Journal:  Osteoporos Int       Date:  2018-12-11       Impact factor: 4.507

2.  A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.

Authors:  Yura Lee; Kyoung Jun Bae; Hae Jung Chon; Seong Hwan Kim; Soon Ae Kim; Jiyeon Kim
Journal:  Mol Cells       Date:  2016-03-30       Impact factor: 5.034

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.